Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
MELBOURNE, Australia., Dec. 5, 2016 /CNW/ -- Propanc Health Group (OTCQB:PPCH), based in Melbourne, focused on the development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian, and colorectal cancers, today announced that the December 1 presentation from James Nathanielsz, Chief Executive Officer, is now available for on-demand viewing at VirtualInvestorConferences.com.
Propanc's presentation will be available 24/7 for 90 days. Investors and advisors may download shareholder materials from the "virtual trade booth" for the next three weeks.
Recent Company Activity:
- Filed applications for Orphan Medicinal Product Designation (OMPD) to the European Medicines Agency (EMA) for PRP, a solution for intravenous administration of pancreatic proenzymes trypsinogen and chymotrypsinogen. The proposed orphan drug indication for PRP is for the treatment of ovarian and pancreatic cancer, responsible for 338,000 cancer diagnoses and 331,000 deaths worldwide in 2012, and a major unmet medical issue.
- Completed a 28 day toxicokinetic study to support determination of a safe starting dose in patients as the Company progresses towards clinical trials in 2017 for its lead product, PRP.
- Executed a contract manufacturing agreement with AmatsiQBiologicals, based in Gent, Belgium. The agreement covers the development and GMP (Good Manufacturing Practice) production of certain enzymes for development purposes, including but not limited to first-in-man studies for the Company's lead product, PRP.
To be added to Propanc's distribution list, please email [email protected] with 'Propanc' in the subject line.
To view the new Propanc video "Mechanism of Action" on anti-cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
About Propanc Health Group
Propanc is developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a formulation of anti-cancer compounds, which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. The products involve or employ pancreatic proenzymes, which are inactive precursors of enzymes.
In the near term, the Company intends to target patients with limited remaining therapeutic options for the treatment of solid tumors. In the future, it intends to develop its lead product to treat (i) early stage cancer, (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, visit: www.propanc.com
SOURCE Propanc Health Group
For further information: Phil Carlson, KCSA Strategic Communications, 212-896-1233, [email protected]; VirtualInvestorConferences.com, Bradley H. Smith, Director of Marketing, IR and Compliance Services, PR Newswire, +1.201.947.7157, [email protected], http://www.propanc.com